THE PIPELINE PAPERS Issue No. 1

Dear Reader, It has come to our attention that this season’s industry revelations are quite extraordinary. Pray, allow us to illuminate the proceedings.

🌱Act I: FROM PLEDGES TO HARD NUMBERS: 2026 SUSTAINABILITY PRIORITIES

Across big pharma, sustainability has shifted from ESG slideware to a strategic operational imperative. Industry surveys and commentary confirm that 2026 agendas are dominated by three priorities: decarbonising energy-intensive manufacturing, tackling Scope 3 (value-chain) emissions, and translating ambitions into credible, auditable metrics (DCATVCI, 2026; Fierce Pharma, 2022).

Scope 3 now represents the majority of emissions for most pharmaceutical companies, forcing deeper collaboration and data-sharing with suppliers across every stage — from raw materials through end-of-life of devices and packaging. Industry leaders consistently note that the largest barrier is not intent but the absence of robust metrics, consistent reporting standards, and clear financial business cases for decarbonisation initiatives (Fierce Pharma, 2022).

The growing importance of third-party ratings and science-based targets — including EcoVadis and the Science Based Targets initiative (SBTi) — is reinforcing the need for rigorous, verifiable data. Pharma sustainability events this spring, including Pharma Sustainability Integrates 2026 (London) and The Pharma Sustainability Days, reflect industry-wide recognition that sustainability performance is now both a competitive differentiator and a supplier-qualification criterion (Life Science Integrates, 2026).

📰Act II: TECHNOECONOMIC ASSESSMENT GOES “ECO-DESIGN BY DEFAULT”

A defining trend this season is the integration of environmental metrics directly into technoeconomic models, rather than treating them as post-optimisation add-ons. This represents a fundamental shift in how process development teams frame decision-making.

Digital platforms such as BioSolve Process (Biopharm Services) exemplify this approach. Early-stage models can now predict total facility energy usage, global warming potential (GWP), water consumption, and manufacturing economics from limited lab-scale data — enabling teams to screen process options simultaneously on both cost and carbon (Biopharm Services, 2025). Applications include comparing fed-batch versus perfusion configurations, stainless steel versus single-use systems, and continuous versus batch downstream processing. Sensitivity analyses identify which parameters — titer, step yield, cleaning frequency, cleanroom classification — move COGS and environmental footprint in opposing directions, revealing true trade-off surfaces (Biopharm Services, 2025).

The key implication for process development teams is stark: economic superiority alone is no longer sufficient to advance a platform internally. New manufacturing approaches must demonstrate wins — or acceptable trade-offs — across both process mass intensity (PMI) and lifecycle environmental impact to secure leadership buy-in (Biopharm Services, 2025).

✨Biopharm Services Spotlight

Biopharm Services continues to lead the discourse on sustainable bioprocess economics. BioSolve Process — their flagship technoeconomic modelling platform — now provides integrated CO₂e, PMI, and water-use outputs alongside traditional COGS analysis. The recently launched Eco Insight database offers validated emission factors for biopharmaceutical materials and consumables, supporting ISO 14067-compliant regulatory submissions. Alpha testing is underway — those wishing to secure an early audience are encouraged to request a demonstration at biopharmservices.com.

Key References

1. Biopharm Services. Sustainability Interview – Life Cycle Assessment. Published 1 April 2025. https://biopharmservices.com/sustainability-interview-life-cycle-assessment/

2. Biopharm Services. Assessing Sustainability Using BioSolve Process for over 10 Years. https://www.biopharmservices.com/assessing-sustainability-using-biosolve-process-for-over-10-years/

3. Biopharm Services. Integrating Eco-Design in Bioprocess Development. Published 11 February 2025. https://biopharmservices.com/integrating-eco-design-in-bioprocess-development/

4. Biopharm Services. Sustainability Metrics. Published 18 August 2024. https://www.biopharmservices.com/sustainability-metrics/

5. Biopharm Services Blog. BioSolve Process: Process Model Evolution. 2023. https://biopharmservices.com/category/blog/feed/

6. Fierce Pharma. Pharma committed on climate sustainability, but barriers remain. Published 8 December 2022. https://www.fiercepharma.com/marketing/pharma-putting-its-money-where-its-mouth-climate-sustainability-barriers-remain

7. Fierce Pharma. Implementing Sustainability Across the Drug Delivery Product Value Chain. https://www.fiercepharma.com/editorial/implementing-sustainability-across-the-drug-delivery-product-value-chain

8. 12. Life Science Integrates. Pharma Sustainability Integrates 2026. Published 3 March 2026. https://lifescienceintegrates.com/event/pharma-sustainability-integrates-2026/

Sources verified from publicly available industry news, trade publications, and company communications as of 24 March 2026.

Some contents are generated by help of AI.

🗣️Until next season, dear reader — may your pipelines be plentiful and your carbon footprint decidedly slim.

XOXO, The Pipeline Papers